Longevity Biotech, Inc
Disease-modifying therapeutics for neurodegenerative diseases
- Sector
- Biotech
- Headquarters
- PHILADELHIA, PA
- Founded
- 2010
- Latest Form D
- $170K, Apr 2011
- Total capital
- $1.4M
- Federal grants
- $886K
- 1 award · 2015
- Rank in peer group#25 of 517
- Private capital raised
- $170K
- 1 Form D · last Apr 2011
- 186 months since last filing
- Federal contracts
- $348K
- 1 award · Health and Human S
- Rank in Biotech#250 of 4373
- Granted patents
- 4
- 7 pending · first 2017
- Rank in peer group#23 of 517
Capital timeline
Latest events
- Federal contractHealth and Human S · Igf::ot::igf$348K
- Federal grantNSF · Phase II · SBIR Phase II: Novel approach to the oral delivery of biologically active peptide analogs$886K
- Private capital raisedForm D · SEC · 1st filing$170K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 517 peers
Line = medianBiotech · Molecule
- Federal grants#25 · top 5%
- Granted patents#23 · top 4%
- Linked publications#25 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Scott ShandlerResearcherExecutive Officer, DirectorLinked by 3 patents · $886K in grants as PI
- Sam GellmanExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 11- PendingHighly Active Polypeptides And Methods Of Making And Using The SameUSPTOApplication 17703770
- PendingPeptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameUSPTOApplication 17650894
- GrantedPeptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameUSPTOUS 11,278,595
Show all 11 patent records
- Highly Active Polypeptides And Methods Of Making And Using The SameNov 14, 2024 · Application 17703770Pending
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameMar 16, 2023 · Application 17650894Pending
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameMar 22, 2022 · US 11,278,595Granted
- Highly Active Polypeptides And Methods Of Making And Using The SameJul 8, 2021 · Application 16940610Pending
- Highly Active Polypeptides And Methods Of Making And Using The SameSep 15, 2020 · US 10,772,934Granted
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameJan 28, 2020 · US 10,543,255Granted
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameOct 17, 2017 · US 9,789,164Granted
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameApplication PCTUS2014030527Pending
- Peptides Comprising Non-natural Amino Acids And Methods Of Making And Using The SameApplication 61801635Pending
- Compositions Comprising Glucagon Analogs And Methods Of Making And Using The SameApplication PCTUS2012032441Pending
- Highly Active Polypeptides And Methods Of Making And Using The SameApplication PCTUS2011033684Pending
Recent research by its founders
- A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease201951 cites
- Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease201621 cites
- Manganese-enhanced magnetic resonance imaging detects VIPR2-mediated immune transformation in a model of Parkinson’s disease20160 cites
Related companies, and why
- NUVOX PHARMA, L.L.C.Similar federal contract value in Biotech · $356K in contracts
- CLOVERLEAF BIO, INC.Similar federal contract value in Biotech · $355K in contracts
- MATRISOME BIO, INC.Similar federal contract value in Biotech · $354K in contracts
- GENOMIC EXPRESSION INCSimilar federal contract value in Biotech · $340K in contracts
- AFASCI, INC.Similar federal contract value in Biotech · $339K in contracts
- Telesis Bio Inc.Similar federal contract value in Biotech · $337K in contracts
Press
Investors pour over $30bn into longevity biotech as report predicts longevity drugs from 2035PRNewswire
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .